Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment
NCT07464340
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
68
Enrollment
INDUSTRY
Sponsor class
Conditions
Bioequivalence Study in Healthy Subjects
Interventions
DRUG:
Rivastigmine TDS 9,5 mg/24 h
DRUG:
Exelon® 9.5 mg/24 h
Sponsor
Zodiac Produtos Farmaceuticos S.A.